Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C

Chang Gung Medical Journal

Volumn 33, Issue 3, 2010, Pages 258-265

  Chen, Chih Hung ^a   Lee, Chuan Mo ^a   Chen, Chien Hung ^a   Hu, Tsung Hui ^a   Wang, Jing Houng ^a   Hung, Chao Hung ^a   Chung, Ching Hu ^b   Lu, Sheng Nan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Antinuclear antibody; Antiviral therapy; Hepatitis C; Smooth muscle antibody; Sustained virological response

Indexed keywords

ALPHA2B INTERFERON; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; PEGINTERFERON; REBETAL; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; SMOOTH MUSCLE ANTIBODY; UNCLASSIFIED DRUG; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SENESCENCE; TREATMENT OUTCOME; BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS C, CHRONIC; IMMUNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SMOOTH MUSCLE; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MUSCLE, SMOOTH; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 77954485084     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32 Suppl 1:98-112.
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
3. Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125-43.
4. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999;31 Suppl 1:39-42.
5. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997;26:689-701.
6. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, Bonkovsky HL. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21:613-9.
7. Bogdanos DP, Mieli-Vergani G, Vergani D. Virus, liver and autoimmunity. Dig Liver Dis 2000;32:440-6.
8. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, Muratori L, Lenzi M, Bianchi G, Zauli D, Bianchi FB. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997;26:561-6.
9. Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, Bianchi FB, Tiribelli C. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999;45:435-41.
10. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-98.
11. Luo JC, Hwang SJ, Li CP, Lu RH, Chan CY, Wu JC, Chang FY, Lee SD. Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J Gastroenterol Hepatol 1998;13:475-9.
12. Hwang SJ, Chu CW, Huang DF, Lan KH, Chang FY, Lee SD. Genetic predispositions for the presence of cryoglobulinemia and serum autoantibodies in Chinese patients with chronic hepatitis C. Tissue Antigens 2002;59:31-7.
13. Hsieh MY, Dai CY, Lee LP, Huang JF, Tsai WC, Hou NJ, Lin ZY, Chen SC, Wang LY, Chang WY, Chuang WL, Yu ML. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008;61:333-7.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
16. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK; Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
17. Wada M, Kang KB, Kinugasa A, Shintani S, Sawada K, Nishigami T, Shimoyama T. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C? Intern Med 1997;36:248-54.
18. Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C, Lorenzen J, Matern S, Lammert F. The presence of nonorgan-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004;4:4.
19. Muratori P, Muratori L, Guidi M, Granito A, Susca M, Lenzi M, Bianchi FB. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis 2005;40:501-7.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
21. Peng YC, Hsieh SC, Yang DY, Tung CF, Hu WH, Huang WN, Chen GH. Expression and clinical significance of antinuclear antibody in hepatitis C virus infection. J Clin Gastroenterol 2001:33:402-6.
22. Bogdanos DP, McFarlane IG. Cytochrome P450 2A6 meets P450 2D6: an enigma of viral infections and autoimmunity. J Hepatol 2003;39:860-3.
23. Hu KQ, Yang H, Lin YC, Lindsay KL, Redeker AG. Clinical profiles of chronic hepatitis C in a major county medical center outpatient setting in the United States. Int J Med Sci 2004;1:92-100.
24. Fried MW, Draguesku JO, Shindo M, Simpson LH, Banks SM, Hoofnagle JH, Di Bisceglie AM. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci 1993;38:631-6.
25. Tomer Y, Shoenfeld Y. Ageing and autoantibodies. Autoimmunity 1988;1:141-9.
26. Antel JP, Oger JJ, Dropcho E, Richman DP, Kuo HH, Arnason BG. Reduced T-lymphocyte cell reactivity as a function of human aging. Cell Immunol 1980;54:184-92.
27. Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A, Chiaramonte M, Braconier JH, Hall AJ, Thursz MR. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 2004;11:459-64.
28. Noda K, Enomoto N, Arai K, Masuda E, Yamada Y, Suzuki K, Tanaka M, Yoshihara H. Induction of antinu-clear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol 1996;31:716-22.
29. Schapiro GD, Friedman LS. Autoimmune hepatitis and/or hepatitis C: how to decide. Hepatology 1996;23:647-9.
30. Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartín P. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol 1996;24:308-12.